CM
CHRS icon

CM Management’s Coherus Oncology CHRS Stock Holding History

CM Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94M Hold
2,100,000
– – 1.87% 13
2026
Q1 		$3.55M Hold
2,100,000
– – 2.97% 7
2025
Q4 		$2.98M Hold
2,100,000
– – 2.51% 10
2025
Q3 		$3.44M Sell
2,100,000
-150,000
-7% -$167K 2.87% 8
2025
Q2 		$1.65M Buy
2,250,000
+102,500
+5% +$88.5K 1.5% 25
2025
Q1 		$1.73M Buy
2,147,500
+97,500
+5% +$112K 1.74% 26
2024
Q4 		$2.83M Buy
2,050,000
+50,000
+3% +$56.1K 2.53% 13
2024
Q3 		$2.08M Buy
2,000,000
+900,000
+82% +$1.23M 1.66% 28
2024
Q2 		$1.9M Buy
1,100,000
+100,000
+10% +$201K 1.75% 23
2024
Q1 		$2.39M Buy
1,000,000
+176,000
+21% +$433K 2.01% 18
2023
Q4 		$2.74M Buy
824,000
+276,000
+50% +$739K 2.21% 13
2023
Q3 		$2.05M Buy
548,000
+98,000
+22% +$453K 2.17% 15
2023
Q2 		$1.92M Buy
450,000
+250,000
+125% +$1.48M 1.87% 18
2023
Q1 		$1.37M Buy
200,000
+25,000
+14% +$194K 1.62% 20
2022
Q4 		$1.39M Sell
175,000
-25,000
-13% -$192K 1.66% 17
2022
Q3 		$1.92M Hold
200,000
– – 2.15% 16
2022
Q2 		$1.45M Buy
200,000
+50,000
+33% +$435K 1.54% 25
2022
Q1 		$1.94M Buy
150,000
+25,000
+20% +$318K 1.63% 23
2021
Q4 		$2M Hold
125,000
– – 1.51% 19
2021
Q3 		$2.01M Buy
125,000
+25,000
+25% +$366K 1.5% 17
2021
Q2 		$1.38M Buy
100,000
+25,000
+33% +$354K 1% 34
2021
Q1 		$1.1M Buy
75,000
+15,000
+25% +$255K 0.81% 49
2020
Q4 		$1.04M Buy
+60,000
New +$1.07M 0.97% 33

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

CM Management's CHRS Position: Q2 2026 in Review

CM Management held its Coherus Oncology (CHRS) position steady in Q2 2026 at 2,100,000 shares worth $2.94M. The position accounts for 1.87% of the portfolio, ranked #13.

CM Management first reported a position in CHRS in Q4 2020 and has held it in 23 quarters since. The position peaked at $3.55M in Q1 2026. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • CM Management held 2,100,000 shares of Coherus Oncology worth $2.94M as of Q2 2026.
  • CM Management left its Coherus Oncology share count unchanged in Q2 2026.
  • Coherus Oncology made up 1.87% of CM Management's portfolio in Q2 2026, its #13 holding.
  • CM Management first reported a position in Coherus Oncology in Q4 2020 and has held it in 23 quarters since.
  • CM Management's Coherus Oncology position peaked at $3.55M in Q1 2026.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on CM Management's 13F filing for Q2 2026, filed 13 Aug 2026.